Sort
50,496 grants matching “lung cancer”
Spatiotemporal regulation of polyploidy in zebrafish cardiac tissue regeneration
$695,387Jingli Cao · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · HL
124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer
$695,342Steven M Larson · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA
124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer
$695,342Steven M Larson · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation
$695,333Katerina Abigail Politi · Yale University · R01 · FY2020 · CA
Probabilistic Multiscale Modeling of the Tumor Microenvironment
$695,214Wesley Tansey · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA
Taxi Health Access Interventions for Linkages and Lifestyle (HAILL)
$695,124Francesca M Gany · Sloan-Kettering Inst Can Research · R01 · FY2018 · NR
3D genome reorganization drives cancer development
$695,123Mandar Deepak Muzumdar · Yale University · R01 · FY2024 · CA
3D genome reorganization drives cancer development
$695,122Mandar Deepak Muzumdar · Yale University · R01 · FY2025 · CA
Project 2: Health Effects of As Cohort Study
$695,078Habibul Ahsan · Columbia University Health Sciences · P42 · FY2009 · ES
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$695,031William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2009 · CA
Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer
$695,004John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Urate as a Predictor of Parkinson's Disease Risk and Progression
$694,904Alberto Ascherio · Harvard School Of Public Health · R01 · FY2012 · NS
Integrating Tobacco Treatment into Cancer Care
$694,888Elyse R Park · Massachusetts General Hospital · R01 · FY2016 · CA
Buccal Nanocytological Risk Stratification to Personalize Lung Cancer Screening
$694,885Hariharan Subramanian · Nanocytomics, Llc · R44 · FY2017 · CA
Sex/Gender and Nicotine Addiction: Hormones, Behavior and Neuroimaging
$694,837Nancy K. Mello · Mclean Hospital · R01 · FY2011 · DA
Role of necrosis in the evolution of highly metastatic and chemo-resistant breast cancers
$694,795Kevin Jon Cheung · Fred Hutchinson Cancer Center · R01 · FY2025 · CA
NANOPHOTOSENSITIZERS FOR REGENERATIVE PHOTOTHERAPY
$694,789Samuel Achilefu · Ut Southwestern Medical Center · R01 · FY2024 · CA
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer
$694,745Bogdan Olenyuk · Proteogenomics Research Instit/Sys/ Med · R01 · FY2022 · CA
MOUNT SINAI COMMUNITY CLINICAL ONCOLOGY PROGRAM
$694,705Mount Sinai Medical Center (Miami Beach) · U10 · FY2002 · CA
Risk Factors for Venous Thromboembolism in the Community
$694,657Aneel Ashrani · Mayo Clinic Rochester · R01 · FY2019 · HL
Risk Factors for Venous Thromboembolism in the Community
$694,655Aneel Ashrani · Mayo Clinic Rochester · R01 · FY2017 · HL
Risk Factors for Venous Thromboembolism in the Community
$694,654Aneel Ashrani · Mayo Clinic Rochester · R01 · FY2016 · HL
Stroger Hospital of Cook County, MBCCOP
$694,625Thomas Lad · Hektoen Institute For Medical Research · U10 · FY2012 · CA
Protein Structure, Stability, and Amyloid Formation
$694,543Ruth Nussinov · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma
$694,475Hamid Ghandehari · Theratarget · R42 · FY2017 · CA